Medpace Holdings, Inc. (MEDP) Stock Analysis
Recovery setup
Healthcare · Diagnostics & Research
Hold if already holding. Not a fresh buy at $461.60, but acceptable to hold if already in. Reasons: Concentration risk — Customer: small biopharmaceutical companies (82.0%); Analyst target reached - limited upside remaining.
Medpace Holdings provides full-service Phase I-IV clinical trial services to biotech, pharma, and medical device companies across 46 countries, employing approximately 6,200 staff. Revenue comes from fixed-fee clinical trial contracts; 82% of 2025 net revenue derived from small... Read more
Hold if already holding. Not a fresh buy at $461.60, but acceptable to hold if already in. Reasons: Concentration risk — Customer: small biopharmaceutical companies (82.0%); Analyst target reached - limited upside remaining. Chart setup: Death cross but MACD improving, RSI 70. Maintain position. Not compelling to add more. Score 5.7/10, moderate confidence.
Passes 7/11 gates (positive momentum, clean insider activity, positive momentum, news events none recent, earnings proximity 35d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-06-17Recent Developments — Medpace Holdings, Inc.
Latest news
- NEWS MEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit - InsideNoVa.com — InsideNoVa.com negative
- NEWS Medpace Holdings (MEDP) Reports Strong Q1 Earnings Amid Leadersh - GuruFocus — GuruFocus positive
- NEWS Medpace’s (NASDAQ:MEDP) Q1 CY2026 Sales Beat Estimates But Stock Drops 19.8% - StockStory — StockStory positive
- NEWS Medpace’s (NASDAQ:MEDP) Q1 CY2026 Sales Beat Estimates But Stock Drops 19.8% - Yahoo! Finance Canada — Yahoo! Finance Canada positive
- NEWS Medpace’s (NASDAQ:MEDP) Q1 CY2026 Sales Beat Estimates But Stock Drops 19.8% - Yahoo Finance — Yahoo Finance positive
Generated 2026-06-17T11:36:49Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomersmall biopharmaceutical companies82%10-K Item 1A: '82% and 13% of our net revenue was derived from small biopharmaceutical companies and mid-sized biopharmaceutical companies, respectively'
- MEDIUMCustomertop ten customers35%10-K Item 1A: 'we derive approximately 35.1% of our net revenue from our top ten customers'
Material Events(8-K, last 90d)
- 2026-06-04Item 5.02LOWBrad W. Hansman (age 43) appointed EVP Operations effective June 1, 2026, to perform principal operating officer functions alongside existing EVP Susan Burwig. Internal promotion from Senior Vice President. No departing officer.SEC filing →
- 2026-04-22Item 5.02MEDIUMJesse Geiger notified intent to resign as President, effective May 31, 2026, to retire. No successor named in available filing text. No disagreement with Company cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $461.60, but acceptable to hold if already in. Reasons: Concentration risk — Customer: small biopharmaceutical companies (82.0%); Analyst target reached - limited upside remaining. Chart setup: Death cross but MACD improving, RSI 70. Maintain position. Not compelling to add more. Target $469.71 (+1.8%), stop $430.04 (−7.3%), A.R:R -1.3:1. Score 5.7/10, moderate confidence.
Take-profit target: $469.71 (+1.8% upside). Target $469.71 (+1.8%), stop $430.04 (−7.3%), A.R:R -1.3:1. Stop-loss: $430.04.
Concentration risk — Customer: small biopharmaceutical companies (82.0%); Analyst target reached - limited upside remaining; Expensive valuation.
Medpace Holdings, Inc. trades at a P/E of 29.1 (forward 24.9). TrendMatrix value score: 3.9/10. Verdict: Hold.
20 analysts cover MEDP with a consensus score of 3.6/5. Average price target: $443.
What does Medpace Holdings, Inc. do?Medpace Holdings provides full-service Phase I-IV clinical trial services to biotech, pharma, and medical device...
Medpace Holdings provides full-service Phase I-IV clinical trial services to biotech, pharma, and medical device companies across 46 countries, employing approximately 6,200 staff. Revenue comes from fixed-fee clinical trial contracts; 82% of 2025 net revenue derived from small biopharmaceutical clients.